Astellas Receives Positive CHMP Opinion For Zolbetuximab In Combination With Chemotherapy For Treatment Of Advanced Gastric And Gastroesophageal Junction Cancer
Portfolio Pulse from Benzinga Newsdesk
Astellas Pharma has received a positive opinion from the CHMP for its drug zolbetuximab, which targets CLDN18.2, for the treatment of advanced gastric and gastroesophageal junction cancer. If approved by the European Commission, it would be the first CLDN18.2-targeted therapy in the EU, with a decision expected by October 2024.
July 26, 2024 | 3:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Astellas Pharma's zolbetuximab has received a positive opinion from the CHMP for treating advanced gastric and gastroesophageal junction cancer. If approved, it would be the first CLDN18.2-targeted therapy in the EU, potentially boosting Astellas' market position.
The positive CHMP opinion is a significant regulatory milestone for Astellas Pharma. If the European Commission approves zolbetuximab, it will be the first CLDN18.2-targeted therapy in the EU, likely enhancing Astellas' market position and revenue potential in the oncology sector.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100